tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Invex Therapeutics Requests Voluntary Suspension Pending Major Announcement

Story Highlights
Invex Therapeutics Requests Voluntary Suspension Pending Major Announcement

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Invex Therapeutics Ltd. ( (AU:IXC) ).

Invex Therapeutics Limited has requested a voluntary suspension of its securities from quotation on the ASX, effective immediately. This suspension is pending an upcoming announcement regarding a significant acquisition and responses to a price query from the ASX, with trading expected to resume by September 29, 2025.

More about Invex Therapeutics Ltd.

Invex Therapeutics Limited operates in the biotechnology sector, focusing on developing innovative therapies for neurological conditions. The company is primarily engaged in research and development activities aimed at addressing unmet medical needs in the market.

Average Trading Volume: 65,890

Technical Sentiment Signal: Buy

Current Market Cap: A$11.65M

Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1